474791 | InSolution™ MG-132 - CAS 133407-82-6 - Calbiochem

474791
No pudo obtenerse el precio
Minimum Quantity needs to be mulitiple of
Al finalizar el pedido Más información
Ahorró ()
 
Solicitar precio
Disponibilidad a confirmar Disponibilidad a confirmar
Suspendido
Cantidades limitadas disponibles
Debe confirmarse disponibilidad
    Remaining : Will advise
      Se avisará
      Ver precios y disponibilidad
         CompararClick To Print This Page

      Overview

      Replacement Information

      Tabla espec. clave

      Fórmula empírica Nº CAS
      C₂₆H₄₁N₃O₅133407-82-6

      Precios y disponibilidad

      Número de referenciaDisponiblidad Embalaje Cant./Env. Precio Cantidad
      474791-1MG
      Comprobando disponibilidad...
      Disponibilidad a confirmar Disponibilidad a confirmar
      Suspendido
      Cantidades limitadas disponibles
      Debe confirmarse disponibilidad
        Remaining : Will advise
          Se avisará

          1 mg
          Recuperando precio...
          No pudo obtenerse el precio
          Minimum Quantity needs to be mulitiple of
          Al finalizar el pedido Más información
          Ahorró ()
           
          Solicitar precio
          474791-5MG
          Comprobando disponibilidad...
          Disponibilidad a confirmar Disponibilidad a confirmar
          Suspendido
          Cantidades limitadas disponibles
          Debe confirmarse disponibilidad
            Remaining : Will advise
              Se avisará

              5 mg
              Recuperando precio...
              No pudo obtenerse el precio
              Minimum Quantity needs to be mulitiple of
              Al finalizar el pedido Más información
              Ahorró ()
               
              Solicitar precio
              Descripción
              Número de catálogo 474791
              Marca de familia Calbiochem®
              Sinónimos Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
              Referencias bibliográficas
              Referencias bibliográficas Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.
              Información del producto
              Número de CAS 133407-82-6
              ATP Competitivo N
              Formulario Liquid
              Formulación A 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
              Fórmula Hill C₂₆H₄₁N₃O₅
              Fórmula química C₂₆H₄₁N₃O₅
              Molar Mass 475.6
              Reversible Y
              Aplicaciones
              Información biológica
              Objetivo principal proteasome
              Objetivo principal IC50 3 µM in inhibiting NF-κB activation
              Objetivo principal K50 4 nM as proteasome inhibitor
              Pureza ≥98% by HPLC
              Información fisicoquímica
              Permeabilidad celular Y
              Dimensiones
              Información de materiales
              Información toxicológica
              Información de seguridad según el GHS
              Información de seguridad
              Frase R R: 36/38

              Frase S S: 26-36-45



              Declaraciones de uso del producto
              Información de almacenamiento y transporte
              Código de envío Blue Ice Only
              Toxicidad Irritant
              Almacenamiento -20°C
              Proteger de la luz Protect from light
              No congelar No
              Instrucciones especiales Following initial thaw, aliquot and freeze (-20°C).
              Información sobre embalaje
              Envasado en atmósfera inerte Packaged under inert gas
              Información de transporte
              Información complementaria
              Especificaciones

              Documentation

              Ficha datos de seguridad (MSDS)

              Idiomas
              Argentina Australia Bahasa Melayu
              Belgie Belgien Belgique
              Brasil Canadian English Canadian-French
              Ceská Rep Chile China
              Colombia Cyprus Danmark
              Danmark Deutschland Deutschland
              Eesti Ellas Ellas
              English España España
              France France Hrvatska 
              Iceland India Indonesia
              Italia Italia Korea
              Korea Latvija Lietuva
              Magyarország Magyarország Malaysia
              Malta México Nederland 
              Nederland  Norge Norge
              Peru Polska Polska
              Portugal Portugal Romania
              Schweiz Slovenija Slovensko
              South Africa Srpski Standard EU English
              Suisse Suomi Suomi
              Sverige Sverige Svizzera
              Taiwan Thailand Türkiye
              US English US Español United Kingdom
              Venezuela Vietnamese Éire
              Österreich България България
              Россия

              Certificados de análisis

              CargoNúmero de lote
              474791

              Referencias bibliográficas

              Visión general referencias
              Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.

              Citas

              Título
            • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
            • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
            • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
            • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
            • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
            • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
            • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
            • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.
            • Ficha técnica

              Note that this data sheet is not lot-specific and is representative of the current specifications for this product. Please consult the vial label and the certificate of analysis for information on specific lots. Also note that shipping conditions may differ from storage conditions.

              Revisión 03-June-2013 JSW
              Sinónimos Carbobenzoxy-L-leucyl-L-leucyl-L-leucinal, Z-LLL-CHO, Proteasome Inhibitor XI
              Descripción Potent, reversible, and cell-permeable proteasome inhibitor (Ki = 4 nM). Reduces the degradation of ubiquitin-conjugated proteins in mammalian cells and permeable stains of yeast by the 26S complex without affecting its ATPase or isopeptidase activities. Activates c-Jun N-terminal kinase (JNK1) and inhibits NF-κB activation (IC50 = 3 µM).
              Formulario Liquid
              Formulación A 10 mM (1 mg/210 µl) or (5mg/1050 µl) solution of MG-132 (Cat. No. 474790) in DMSO.
              Gas inerte (Sí/No) Packaged under inert gas
              Número de CAS 133407-82-6
              Masa molar 475.6
              Fórmula química C₂₆H₄₁N₃O₅
              Pureza ≥98% by HPLC
              Almacenamiento -20°C
              Protect from light
              Do Not Freeze No
              Special Instructions Following initial thaw, aliquot and freeze (-20°C).
              Toxicidad Irritant
              Referencias bibliográficas Meriin, A.B., et al. 1998. J. Biol. Chem. 273, 6373.
              Adams, J., and Stein, R. 1996. Ann. Rep. Med. Chem. 31, 279.
              Lee, D.H., and Goldberg, A.L. 1996. J. Biol. Chem. 271, 27280.
              Wiertz, E.J.H.J., et al. 1996. Cell 84, 769.
              Read, M.A., et al. 1995. Immunity 2, 493.
              Rock, K.L., et al. 1994. Cell 78, 761.
              Cita
            • Yolanda Fernandez, et al. (2006) Chemical Blockage of the Proteasome Inhibitory Function of Bortezomib: Impact on Tumor Cell Death. Journal of Biological Chemistry 281, 1107-1118.
            • Markus D. Lacher, et al. (2006) Transforming Growth Factor-{beta} Receptor Inhibition Enhances Adenoviral Infectability of Carcinoma Cells via Up-Regulation of Coxsackie and Adenovirus Receptor in Conjunction with Reversal of Epithelial-Mesenchymal Transition. Cancer Research 66, 1648-1657.
            • Liwei Chen, et al. (2005) Chemical ablation of androgen receptor in prostate cancer cells by the histone deacetylase inhibitor LAQ824. Molecular Cancer Therapeutics 4, 1311-1319.
            • Emily I. Chen, et al. (2005) Maspin alters the carcinoma proteome. FASEB Journal in press,.
            • Siva Kumar Kolluri, et al. (2005) The R-enantiomer of the nonsteroidal antiinflammatory drug etodolac binds retinoid X receptor and induces tumor-selective apoptosis. Procedings of the National Academy of Science 102, 2525-2530.
            • Zaibo Li, et al. (2005) VHL protein-interacting deubiquitinating enzyme 2 deubiquitinates and stabilizes HIF-1α. European Molecular Biology Organization Reports 6, 373-378.
            • Yasuyuki Miyake, et al. (2005) Novel splicing variant of mouse orc1 is deficient in nuclear translocation and resistant for proteasome-mediated degradation. Journal of Biological Chemistry 280, 12643-12652.
            • Chuan-Jin Wu, et al. (2005) TNF-α induced c-IAP1/TRAF2 complex translocation to a Ubc6-containing compartment and TRAF2 ubiquitination. European Molecular Biology Organization Journal 24, 1886-1898.
            • Zhigang Zhang, Jin-Ying Wu, William Hait and Jin-Ming Yang. (2004) Regulation of the stability of P-glycoprotein by ubiquitination.. Molecular Pharmacology 66, 395-403.
            • Gloria Bonuccelli, et al. (2003) Proteasome inhibitor (MG-132) treatment of mdx mice rescues the expression and membrane localization of dystrophin and dystrophin-associated proteins. American Journal of Pathology 163, 1663-1675.